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Pulmonary hypertensionHeart Failure (HF) is a condition in which the ability of the heart
to pump appropriately enough blood to the body is impaired. It
may involve either right ventricle (RV) or left ventricle (LV) or
more often, defect on both sides of the heart, which causes an
altered pathological condition. Regardless of the heart
chamber involved, the normal function of the heart is
compromised and eventually it fails and results in death.
Since the ventricles of the heart are inter-dependent and share
the same septal wall, any dysfunction in LV can inﬂuence the
normal function of RV. Heart failure due to LV dilation or
hypertrophy can potentiate afterload on RV by increasing
pulmonary venous pressure1 and ultimately pulmonary
arterial pressure. In the past, much attention has been given
to study the function of LV and as a result, signiﬁcant
improvement has been made in the treatment of left HF. This
advancement is partly due to the feasibility to measure several
strong reliable and reproducible parameters, such as ejection
fraction (EF), estimated left ventricular end-diastolic pressure
(LVEDp), and LV wall thickness (LVED), using non-invasive and
affordable methods such as echocardiography. However, this
is not the case when measuring right ventricle function.
Diagnosing RV dysfunction by non-invasive procedure is
challenging and often inaccurate.
In addition, the systematic evaluation of right heart
structure and function is not uniformly carried out, especially
due to the complexity in RV imaging and temporal and spatial
arrangement of RV. Moreover, there is no isolated non-
invasive ultrasound-related parameter that can completelyassess right heart function with high ﬁdelity and accuracy.
A comprehensive evaluation through a multi-parameter
approach of RV structure and function is recommended and
needed.
Evaluation of RV structure and function in patient is key not
only to rule out an existence of RV dysfunction, secondary to
LVHF (left ventricle heart failure), but also for the possibility of
co-existence of fatal diseases such as pulmonary hyperten-
sion, pulmonary embolism, and others. Studies indicate
patients classiﬁed as WHO functional class I and II have
improved long-term survival rate than patients in class III and
IV stages of PAH.2 This functional evidence urges and
rationalizes the need for an early diagnosis of right heart
disease such as PAH in patients with LV failure.
Pulmonary hypertension could arise either as a primary
PAH or idiopathic PAH or, most frequently, secondary to left
failing heart. The latter belongs to Group II of Dana Point
Classiﬁcation and is determined by left heart diseases,
including abnormalities such as systolic and/or diastolic
dysfunction and valvular heart disease. Such extensive
pathological changes in blood vessels and ventricles of heart
lead to maladaptation and result in increased pulmonary
vascular resistance (PVR). In spite of a strong positive co-
relation between an early intervention of RH failure (e.g.
PAH) and prolonged extension of survival rate3,4 efforts to
identify these diseases in its preliminary stages remain
poor.
Current available procedures for a reliable measurement of
RV function depend on advanced equipment (e.g. MRI, 3D
Echo) and complex invasive methods, such as right heart
catheterization (RHC), which involves potential complications
mostly related to the venous access (e.g., hematoma, pneu-
mothorax), followed by arrhythmias, hypotensive episodes
(related to vagal reactions or pulmonary vasoreactivity
testing), and more rarely pulmonary embolism.5 Although
these techniques remain the golden standard for an accurate
and trustworthy evaluation of right heart hemodynamics, they
often require admission of patients in the hospital facility or
associated with high medical expenses.
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in the health care centers has facilitated the use of
echocardiography as an alternative option to perform a non-
invasive assessment of RV function, measurement of hemo-
dynamics, and evaluation of structural abnormalities. Several
parameters of right heart chambers that can be measured
using echocardiography are approved as guidelines by WHO
and American Society for Echocardiography6 (ASE) and
recommended for diagnosis and prognosis of treatment.
Among them, tricuspid annular plane systolic excursion7
(TAPSE), tricuspid valve regurgitation (TVR), eccentricity, and
right ventricular free wall systolic strain are widely accepted
right heart indices that manifest PAH disease severity and
survival rate. Other useful parameter such as RV systolic
pressure can be estimated by the analysis of tricuspid
regurgitant jet by the Bernoulli equation: 4v2, where v is the
maximum jet velocity of the tricuspid valve added to the
estimated RA pressure by the dimension and collapsibility of
the inferior cava vein. The mPAP, which is a strong indicator of
PH, can also be measured using modiﬁed Bernoulli equation,8
although as an indirect estimation and therefore should be
conﬁrmed with other advanced techniques. The tricuspid
regurgitant velocity (TR Vel) is also used to estimate the
systolic RV – right atrium gradient. The end diastolic pulmonic
regurgitant velocity is used to estimate diastolic pulmonary
artery pressure (PAPd). This measurement estimates the
pulmonary artery systolic pressure, assuming there is no
evidence of pulmonary valve stenosis or obstruction. Echo-
cardiography can also be used to estimate PVR by taking the
ratio of the tricuspid regurgitant jet velocity to the acceleration
time of the RV ejection into the PA. Echocardiographic
assessment also provides important information about the
RV structure and hemodynamics, which can also suggest the
presence of PH. More classical parameters are enlarged
dimensions of right heart chambers, abnormal shape and
function of the intraventricular septum, increased RV wall
thickness, and a dilated main pulmonary artery. In summary,
several parameters obtained using echocardiography can
provide vital information about right heart function and aid
the diagnosis of RV abnormalities.
Despite advances, there is still uncertain and unmet need
for improvements in the diagnosis of RV failure and coexisting
conditions such as pulmonary hypertension. Screening of
patients at risk of developing RVF and/or PAH (e.g. LV HF)
should be carried out on routine basis using commonly
available methods such as echocardiography to diagnose the
disease at an early stage.
In the recent issue of Indian Heart Journal, a cohort study by
Deveci et al. shows a signiﬁcant decrease of RVOT-FS (right
ventricular outﬂow tract-fractional shortening) in 36 HF
patients with a known dilated heart and LV systolic dysfunc-
tion. Interestingly, the authors also observed a positive
correlation between RVOT-FS and TAPSE, a well-known
predictor of RV dysfunction. The major advantage of this
study is that it recommends an ultrasound derived non-
invasive parameter that was previously validated and is easy
to carry out. However, in this case, the authors recognized a
potential clinical relevance for RVOT-FS in HF patients, giving
insights to the classic discordance of LVEF at rest and
functional class. The strong positive correlation found bythe authors between RVOT-FS and TAPSE ensures that RVOT-
FS provides information about RV function (i.e. contractility).
In light of this observation, RVOT-FS could be very useful in
assessing RV function in situations in which other commonly
used parameters in the ultrasound assessment (i.e. TAPSE or
annular velocity) fail to assess RV contractility (i.e. Severe
tricuspid regurgitation). Though RVOT-FS is not a conclusive
parameter, it offers a vital clue for RV dysfunction and should
be conﬁrmed with additional indices obtained by more precise
and/or complex techniques (MRI, 3D Echo, strain imaging).
Several previous studies have also demonstrated a correlation
between RVOT and RV dysfunction9 and found it as a useful
parameter in the diagnosis of RV-related disease such as
pulmonary embolism.
The authors also provided insights in understanding the
existence of the classic discordance between LVEF and NYHA
class. This explanation could not only help in the prompt
recognition of the failing left heart-associated with RV
dysfunction, but also offer important information concerning
response to medical treatment and recommendation for
further additional invasive or advanced diagnostic test.
As mentioned, by the authors, while measurement of this
parameter does not require any additional skill, there are
often technical difﬁculties in obtaining an accurate image of
the RV walls owing to the complex geometry of RV wall.
Nevertheless, echocardiographic measurement of RVOT
along with FS can be extremely useful parameter to validate
RV dysfunction, when combined with multiple indices such
as TAPSE, PVR, and mPAP, especially in patients with known
LV dysfunction. Addition of RVOT-FS as a standard
parameter in routine echocardiography procedure and
clinical practice can assist in early diagnosis of RV
dysfunction-related disease such as PAH, secondary to left
HF and also as a prognosis of treatment in patients with
established HF.
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